Sichuan Kelun-Biotech Biopharmaceutical Co Ltd, a holding subsidiary of Kelun Pharmaceutical (SZ:002422), announced on Monday that the new drug application (NDA) for its small molecule rearranged during transfection (RET) kinase inhibitor A400 (EP0031) has been accepted for review by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA).
The product is intended for the treatment of adult patients with RET-fusion positive locally advanced, or metastatic non-small cell lung cancer (NSCLC).
This acceptance for review is based on positive results from the two pivotal Phase 2 cohorts of the KL400-I/II-01 study for both 1L and 2L+ advanced RET-fusion positive NSCLC.
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline
ME Therapeutics secures US patent for lead antibody and advances cancer programmes
OSE Immunotherapeutics forms strategic alliance with Inserm Transfert and Nantes University
Eli Lilly receives US FDA approval for Inluriyo
Biostar Pharma gains FDA orphan drug designation for Utidelone in pancreatic cancer
Hoth Therapeutics expands intellectual property portfolio for HT-001 in US
Lunit partners with CellCarta to expand access to digital pathology AI for clinical trials
Veracyte to present first prospective validation data for prostate cancer biomarker at ASTRO 2025
Eli Lilly plans new manufacturing facility in Houston, Texas
Sichuan Kelun-Biotech Biopharmaceutical NDA for A400 accepted for review in China
Akeso showcasing late-breaking abstract from ivonescimab study at ESMO
Tempus secures FDA clearance for RNA-based xR IVD diagnostic device
Regenerative Agriculture Pioneer Bob Jones to Deliver Keynote at Metabolic Health Day Conference